Medidata Champions Real-World AI with Medidata Plus at NEXT Tokyo 2026 to Accelerate Life-Saving Patient Therapies

Medidata, a Dassault Systèmes brand and leading provider of clinical trial solutions to the life sciences industry, will host Medidata NEXT Tokyo 2026 on Tuesday, August 18, 2026, at The Prince Park Tower Tokyo. This premier industry event will move beyond the conceptual phase of AI, showcasing practical, real-world deployments that are transforming clinical development. Through a series of expert-led sessions, Medidata is convening key opinion leaders to address the challenges of data fragmentation and protocol complexity, while unveiling new innovations for the future of clinical research with the purpose of accelerating the delivery of new therapies to patients.

Building on its Study, Patient, and Data Experiences - and leveraging decades of expertise alongside one of the largest clinical datasets from over 38,000 research studies involving more than 12 million patients - this presentation continues momentum at NEXT events across the globe including in New York, Paris, Madrid, Basel, London, San Francisco, Milan, and Seoul.

Medidata Plus is a platform-wide AI layer that unlocks the full breadth of clinical AI capabilities on the Medidata Platform, giving life sciences leaders access to scalable, outcomes-driven AI across their global portfolios. Medidata Plus shifts the industry away from a legacy of disjointed, inefficient point solutions to a unified, end-to-end AI strategy, accelerating the delivery of life-saving therapies to patients.

The life sciences industry is moving from theoretical discussions to demanding measurable outcomes that integrate AI into day-to-day operations to accelerate high-stakes decision-making. This view is supported by the findings of Medidata's second annual report, The State of AI in Clinical Trials© (Japanese), which highlights that 92% of respondents plan to increase AI investment. This independent survey underscores a pivotal shift from the industry-wide deployment of experimental pilots toward a significant competitive advantage for early adopters.

"At NEXT Tokyo, we are showcasing how Medidata leverages decades of historical clinical trial knowledge to answer the most critical questions the industry is asking about AI," said Motohide Nishi, Vice President, Medidata Solutions. "Realizing this potential at scale requires a foundation of connected, intelligent systems that generate seamless operational workflows. We are excited to demonstrate our AI leadership through Medidata Plus and show how we are using our experience to transform every stage of the clinical trial lifecycle, resulting in faster, safer decisions for patients worldwide."

Medidata will also showcase how merging the virtual and real worlds is creating a new era of orchestrated intelligence, a unified approach where every decision is smarter, faster, and seamlessly interconnected for the benefit of clinical study teams. At the core of this are a series of virtual companions and agents that work in coordination across the entire end-to-end lifecycle, arming sponsors, CROs, and partners with a decisive technological edge.

By combining forces, this ecosystem of agents and companions automates complex workflows, such as slashing study build timelines from weeks to hours, and transforms how the industry creates, tests, and validates innovations and business processes. Together, they deliver a new way of working, enabling humans and AI to collaborate safely, intelligently, and at scale to solve highly complex industrial and clinical challenges.

About NEXT Tokyo

NEXT Tokyo 2026 brings together more than 400 Japan life sciences leaders for 1 day of expert and industry-led sessions focused on how AI, Virtual Twins, and orchestrated intelligence are disrupting and reinventing clinical trials to get new therapies to patients with unprecedented accuracy, efficiency, and speed. The conference includes over 20 keynotes, specialized breakouts, and interactive sessions with industry leaders.

About Medidata
Medidata has been powering smarter treatments and healthier people by supporting clinical trials through groundbreaking technological innovations for over 25 years. Medidata is a leader in AI-powered solutions across the entire trial lifecycle to accelerate clinical breakthroughs, reduce patient and site burden, and bring new therapies to market faster. Supported by one of the largest clinical datasets in the industry of more than 38,000 trials and 12 million patients, Medidata's Study, Patient, and Data Experiences are trusted by more than 1 million registered users across approximately 2,300 customers. A Dassault Systèmes brand (Euronext Paris: FR0014003TT8, DSY.PA), Medidata is headquartered in New York City and is recognized as a leader by Everest Group and IDC. Discover more at www.medidata.com. Listen to our latest podcast, from Dreamers to Disruptors, and follow us at @medidata-solutions on LinkedIn.

About Dassault Systèmes
Dassault Systèmes is a catalyst for human progress. Since 1981, the company has pioneered virtual worlds to improve real life for consumers, patients and citizens. Through the 3DEXPERIENCE platform, AI-powered, science-based virtual twins help 390,000 customers of all sizes, in all industries, collaborate, imagine and create sustainable innovations that drive meaningful impact. For more information, visit: www.3ds.com.